Article
Chemistry, Multidisciplinary
Lingxiao Zhang, Shengjie Hou, Fatemeh Movahedi, Zijin Li, Li Li, Jing Hu, Yingbo Jia, Yaru Huang, Jie Zhu, Xiaoying Sun, Linghui Zeng, Ruitian Liu, Zhi Ping Xu
Summary: This research developed two dual-targeted layered double hydroxide (LDH) nanoparticle-based nanomedicines for efficient intervention of Alzheimer's disease (AD). These nanomedicines reduced amyloid beta (Aβ)/hyperphosphorylated Tau burden and neuroinflammation simultaneously, leading to the recovery of memory and cognitive deficits in AD mice.
Article
Immunology
Wangyu Bi, Tong Lei, Shanglin Cai, Xiaoshuang Zhang, Yanjie Yang, Zhuangzhuang Xiao, Lei Wang, Hongwu Du
Summary: This review summarizes the role of astrocytes in Alzheimer's disease (AD) and explores the potential therapeutic strategies targeting astrocytes. Astrocytes play an important role in the pathogenesis of AD, and therapies targeting astrocytes have shown high efficacy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Geriatrics & Gerontology
Wei Xu, Chen-Chen Tan, Xi-Peng Cao, Lan Tan
Summary: The study found that PGRN and neuroinflammatory markers increased over the course of Alzheimer's disease, and neuroinflammation can modulate the association of PGRN with amyloid pathologies. Neuroinflammatory markers significantly modulated the relationship between amyloid burden and CSF PGRN, which could predict cognitive decline and lower AD risk in certain groups.
NEUROBIOLOGY OF AGING
(2021)
Review
Cell Biology
Li-Kai Huang, Yi-Chun Kuan, Ho-Wei Lin, Chaur-Jong Hu
Summary: Alzheimer's disease is a major cause of dementia, and the approval of new drugs through clinical trials has brought hope to patients. Ongoing clinical trials are focused on exploring the treatment of the disease mechanism and early intervention through new drugs.
JOURNAL OF BIOMEDICAL SCIENCE
(2023)
Review
Neurosciences
Guimei Zhang, Zicheng Wang, Huiling Hu, Meng Zhao, Li Sun
Summary: Alzheimer's disease is a common type of age-related dementia, where dysregulated microglia activity can lead to chronic neuroinflammation, promote pathological protein accumulation, and impair mitophagy. Targeting microglia may offer new therapeutic interventions for the disease.
FRONTIERS IN CELLULAR NEUROSCIENCE
(2021)
Article
Clinical Neurology
Nicolai Franzmeier, Rik Ossenkoppele, Matthias Brendel, Anna Rubinski, Ruben Smith, Atul Kumar, Niklas Mattsson-Carlgren, Olof Strandberg, Marco Duering, Katharina Buerger, Martin Dichgans, Oskar Hansson, Michael Ewers
Summary: The study found that carriers of the BIN1 rs744373 risk allele showed faster global tau-PET accumulation and accelerated tau-PET accumulation at higher A beta levels. In the ADNI sample, the effects of rs744373 on cognitive decline were mediated by faster global tau-PET accumulation.
ALZHEIMERS & DEMENTIA
(2022)
Article
Medicine, Research & Experimental
Niklas Mattsson-Carlgren, Shorena Janelidze, Randall J. Bateman, Ruben Smith, Erik Stomrud, Geidy E. Serrano, Eric M. Reiman, Sebastian Palmqvist, Jeffrey L. Dage, Thomas G. Beach, Oskar Hansson
Summary: Plasma levels of phospho-tau217 (P-tau217) accurately differentiate Alzheimer's disease dementia from other dementias, with increasing levels reflecting both beta-amyloid plaques and tau tangles. The correlation between P-tau217 concentrations and beta-amyloid PET is stronger in early disease stages, while in late stages, there is a stronger correlation with both beta-amyloid and tau PET results. P-tau217 mediates the association between beta-amyloid and tau, especially for tau outside of the medial temporal lobe.
EMBO MOLECULAR MEDICINE
(2021)
Review
Genetics & Heredity
Laura Ibanez, Carlos Cruchaga, Maria Victoria Fernandez
Summary: Alzheimer's disease is a common disease of the elderly with no current cure. Research suggests different subgroups of AD may exist, each potentially requiring a different therapeutic approach. Successful prevention and treatment of AD involve identifying pathologic triggers, using biomarkers for accurate monitoring, and developing models that better mimic the complexity of the human brain.
Article
Cell Biology
Hyun-ju Lee, Seong Gak Jeon, Jieun Kim, Ri Jin Kang, Seong-Min Kim, Kyung-Min Han, HyunHee Park, Ki-taek Kim, You Me Sung, Hye Yeon Nam, Young Ho Koh, Minseok Song, Kyoungho Suk, Hyang-Sook Hoe
Summary: Ibrutinib was found to reduce Aβ plaque levels, decrease neuroinflammatory responses, lower tau phosphorylation, improve memory, and promote dendritic spine development in mouse models of Alzheimer's disease, suggesting it may be a potential therapy for AD.
Article
Behavioral Sciences
Xiaoqin Tan, Zhibin Liang, Yingui Li, Yingkun Zhi, Lang Yi, Shasha Bai, Kelly H. Forest, Robert A. Nichols, Yan Dong, Qing X. Li
Summary: Isoorientin, a selective inhibitor of GSK-3 beta, shows therapeutic potential in attenuating AD pathogenic hallmarks and improving cognitive function in transgenic mouse models.
BEHAVIOURAL BRAIN RESEARCH
(2021)
Article
Neurosciences
Lin Lin, Ronald S. Petralia, Lynne Holtzclaw, Ya-Xian Wang, Daniel Abebe, Dax A. Hoffman
Summary: The loss of DPP6 has been found to impact neuronal and synaptic development, leading to Alzheimer's disease-like symptoms in aging mice. The aging DPP6-KO mice exhibit reduced brain and hippocampus size, decreased total neurons, increased neuron death, accumulation of Alzheimer's disease biomarkers, and neuroinflammation. Additionally, circadian dysfunction is observed in these mice.
NEUROBIOLOGY OF DISEASE
(2022)
Review
Neurosciences
Kristian F. Odfalk, Kevin F. Bieniek, Sarah C. Hopp
Summary: This article reviews the intersection between microglia and tau from the perspectives of neuropathology, neuroimaging, genetics, transcriptomics, and molecular biology. Microglia play both positive and negative roles in regulating tau pathology, with the ability to mitigate tau spread by degrading internalized tau seeds, but detrimental consequences occur when these seeds cannot be degraded.
PROGRESS IN NEUROBIOLOGY
(2022)
Review
Psychiatry
Harriet Demnitz-King, Lisa Saba, Yolanda Lau, Lydia Munns, Sedigheh Zabihi, Marco Schlosser, Rafael del-Pino-Casado, Vasiliki Orgeta, Natalie L. Marchant
Summary: This systematic review and meta-analysis examined the association between anxiety symptoms and two defining markers of AD neuropathology: amyloid-beta (Aβ) and tau. The results showed no associations between self-reported anxiety symptoms and either Aβ or tau in cognitively healthy adults. However, larger studies with longer follow-up periods are needed to explore the impact of anxiety symptom onset, severity, and chronicity on AD neuropathology.
JOURNAL OF PSYCHOSOMATIC RESEARCH
(2023)
Article
Medical Laboratory Technology
Anders Abildgaard, Tina Parkner, Cindy Soendersoe Knudsen, Hanne Gottrup, Henriette Klit
Summary: This study found that tau/Aβ 42 ratios have the best diagnostic performance, but the estimated cut-off values for the ratios were slightly higher than previously reported. Therefore, adjustment of the cut-offs may be warranted when using CSF analysis to support a diagnosis of AD in a heterogeneous high-prevalence cohort.
CLINICA CHIMICA ACTA
(2023)
Article
Immunology
Marco Antonio De Bastiani, Bruna Bellaver, Wagner S. Brum, Debora G. Souza, Pamela C. L. Ferreira, Andreia S. Rocha, Guilherme Povala, Joao Pedro Ferrari-Souza, Andrea L. Benedet, Nicholas J. Ashton, Thomas K. Karikari, Henrik Zetterberg, Kaj Blennow, Pedro Rosa-Neto, Tharick A. Pascoal, Eduardo R. Zimmer
Summary: Our study investigated the association between plasma GFAP and Aβ and tau pathology, and conducted transcriptomic analysis on hippocampal GFAP-positive astrocytes in mouse models. The findings suggest unique signatures in GFAP-positive astrocytes associated with Aβ and tau pathologies.
BRAIN BEHAVIOR AND IMMUNITY
(2023)